0001477932-26-001940
SEC filingVolitionRx Limited stockholders approved two key proposals at a special meeting on March 31, 2026, authorizing a significant share issuance and a potential reverse stock split.
The special meeting of stockholders on March 31, 2026, resulted in the approval of two significant corporate actions that will directly impact the company's capital structure and share count. The first proposal authorizes the issuance of a substantial block of shares to Lind Global Asset Management XII LLC, specifically exceeding 20% of the company's outstanding shares, which indicates a major financing transaction or strategic partnership. This approval was necessary for compliance with NYSE American Rule 713, suggesting the transaction involves exchange listing requirements. The second proposal grants the board of directors authority to implement a reverse stock split at a ratio ranging from 1-for-5 to 1-for-20, providing flexibility to adjust the share price for potential listing maintenance or other corporate purposes. The voting results show stronger support for the reverse stock split (approximately 79% of votes cast in favor) compared to the share issuance proposal (approximately 74% of votes cast in favor), with both proposals receiving sufficient votes to pass. The high number of broker non-votes on the first proposal (21,146,445 shares) indicates significant shares held in street name where brokers lacked voting instructions. These approvals provide the company with important tools for capital management and regulatory compliance.